Welcome to
On Feet Nation
smithmorgan Online
Raymond Online
Patricia Online
Christopher Online
Casen Online
jack Online
Posted by smithmorgan on September 15, 2024 at 10:06am 0 Comments 0 Likes
India’s first domestically developed mRNA-based Covid-19 vaccine candidate has been found safe in its interim Phase 1 clinical trials, and the national drugs regulator has granted approval to its maker, Pune-based Gennova Biopharmaceuticals, to begin Phase 2/3 trials, the Union ministry of science and technology said on Tuesday.
The development of HGCO19, the country’s first vaccine based on messenger-RNA (mRNA) technology, is a key step in India’s target of vaccinating all adults by the end of the year as senior government officials have said that — subject to trials and approval — they are looking at availability of 60 million vaccine doses by December.
The candidate could join a club of mRNA-based vaccines currently consisting of just two American vaccines – by Pfizer-BioNTech and Moderna Inc – both of which have the highest efficacy among those currently being administered globally.
https://www.hindustantimes.com/india-news/gennovas-m-rna-vaccine-ge...
© 2024 Created by PH the vintage. Powered by
You need to be a member of On Feet Nation to add comments!
Join On Feet Nation